Access to Clinical Therapeutics
نویسندگان
چکیده
منابع مشابه
Biomarkers to guide clinical therapeutics in rheumatology?
PURPOSE OF REVIEW The use of biomarkers in rheumatology can help identify disease risk, improve diagnosis and prognosis, target therapy, assess response to treatment, and further our understanding of the underlying pathogenesis of disease. Here, we discuss the recent advances in biomarkers for rheumatic disorders, existing impediments to progress in this field, and the potential of biomarkers t...
متن کاملClinical Medicine Insights: Therapeutics
Pegaptanib sodium is a polyethylene-glycolated, 28-nucleotide RNA aptamer that binds selectively to vascular endothelial growth factor (VEGF)165 but not smaller isoforms. Preclinical studies identified VEGF165 as an especially potent promoter of ocular neovascularization and inflammation. Following the pivotal clinical trials demonstrating the efficacy of intravitreal pegaptanib in treating all...
متن کاملClinical Medicine Insights: Therapeutics
The newest antidepressant, desvenlafaxine (DVS) was approved by the FDA in early 2008 and since then, has been available in the market for general use. DVS is dual acting, a serotonin-norepinepherine reuptake inhibitor (SNRI). Like its parent compound, venlafaxine (VEN), DVS inhibits the neuronal re-uptake of both serotonin and norepinepherine while having minimal affinity for muscarinic cholin...
متن کاملClinical Medicine Insights: Therapeutics
Objective: Oxybutynin chloride topical gel (OTG) significantly improved overactive bladder (OAB)–related urinary symptoms and was well tolerated in a phase III double-blind, placebo-controlled trial (ClinicalTrials.gov identifier NCT00350636). This study further evaluated the effect of OTG on health-related quality of life (HRQoL) in adults with OAB. Methods: Adults aged 18 years or older with ...
متن کاملClinical Medicine Insights: Therapeutics
The treatment of moderate to severe Alzheimer’s disease is reviewed with regard to mechanisms of action, pharmacokinetics, metabolism, safety/tolerability, and efficacy in reducing cognitive, behavioral/psychiatric, functional and global symptoms. The cholinesterase inhibitors donepezil, rivastigmine and galantamine and the N-methyl-d-aspartate receptor channel blocker memantine are moderately ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Therapeutics
سال: 2015
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2015.07.009